DMTK

DermTech, Inc. Common Stock

DMTK

Market cap $3.29M

Delisted

DMTK was delisted on the 26th of June, 2024.

Back to rankings

About: DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Employees: 208

Healthcare Diagnostics & Research

Financial journalist opinion

Why Is DermTech (DMTK) Stock Down 26% Today?

DermTech (NASDAQ: DMTK ) stock is falling on Monday as investors prepare for the molecular diagnostic company's shares to be delisted later this week. DermTech received a notice from the Listing Qualifications Department of the Nasdaq Exchange notifying it of its delisting.

Why Is DermTech (DMTK) Stock Down 26% Today?

Crude Oil Rises 1%; DermTech Shares Plummet

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 0.1% on Tuesday.

Crude Oil Rises 1%; DermTech Shares Plummet

DermTech Files for Voluntary Chapter 11 Protection

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DM.

DermTech Files for Voluntary Chapter 11 Protection

DermTech Reports First-Quarter 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue wa.

DermTech Reports First-Quarter 2024 Financial Results

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, lice.

DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech's Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The 2022 Inducement Plan is used exclusively for t.

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California. The first research abstract, “Non-invasive gene expression analyses to rule out melanoma in patients with Fitzpatrick skin types IV-VI” will be prese.

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript

DermTech, Inc. (DMTK) Q4 2023 Earnings Call Transcript

Zacks Investment Research

DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates

DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.

DermTech Reports Fourth-Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. “We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024,” said Bret Christensen, CEO, DermTech. “We've aligned our commercial ef.

DermTech Reports Fourth-Quarter 2023 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™